Millennium Pharmaceuticals, Inc. (South San Francisco, California) Leadership in Proteasome Inhibition Highlighted in Relapsed/Refractory Multiple Myeloma At IMW Meeting

Published: May 05, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported results from three studies in relapsed multiple myeloma (MM). Two of the studies examined the use of VELCADEĀ® (bortezomib) for Injection; the third study presents clinical data on MLN9708, the first investigational oral proteasome inhibitor.

Back to news